NeuroOne Medical Technologies Corporation (NMTC) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with significant improvements in gross margins and a reduced net loss. The strategic plan outlines ambitious growth prospects, including new product developments and market expansions. Although some uncertainty exists around partnerships and timelines, the overall sentiment is optimistic with increased revenue guidance and improved financial health. The Q&A section did not highlight any major concerns, supporting a positive outlook. Given these factors, a positive stock price movement is likely over the next two weeks.
Key Financial Performance
Product Revenue (Q4 FY 2025) $2.7 million, a 907% increase year-over-year. This growth was driven by the expansion of commercialization efforts for the OneRF brain ablation system distributed by Zimmer Biomet.
Product Revenue (Full FY 2025) $9.1 million, a 163% increase year-over-year. The increase was attributed to record product sales growth.
License Revenue (FY 2025) $3 million, compared to no license revenue in FY 2024. This revenue was derived from the expanded exclusive distribution agreement with Zimmer Biomet.
Product Gross Margins (Q4 FY 2025) 55.8%, compared to 51.8% in Q4 FY 2024. The improvement was due to the expansion of commercialization efforts.
Product Gross Margins (Full FY 2025) 56.5%, compared to 31.3% in FY 2024. The significant improvement was attributed to increased product sales and operational efficiencies.
Operating Expenses (Q4 FY 2025) $2.9 million, a 2% decrease year-over-year. This reduction was achieved despite increased commercialization efforts.
Operating Expenses (Full FY 2025) $12.4 million, a 5% decrease year-over-year. The decrease was due to cost management and operational efficiencies.
Net Loss (Q4 FY 2025) $1.6 million or $0.03 per share, a 52% improvement year-over-year. This improvement was driven by increased revenue and reduced operating expenses.
Net Loss (Full FY 2025) $3.6 million or $0.09 per share, a 71% improvement year-over-year. The improvement was due to increased revenue, improved gross margins, and reduced operating expenses.
Cash and Cash Equivalents (as of September 30, 2025) $6.6 million, compared to $1.5 million as of September 30, 2024. The increase was due to an $8.2 million capital raise.
Working Capital (as of September 30, 2025) $7.9 million, compared to $2.4 million as of September 30, 2024. The improvement was driven by increased cash reserves and no outstanding debt.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA 510(k) clearance for OneRF trigeminal nerve ablation system: Received clearance for treating facial pain, with successful initial patient treatments and positive outcomes.
Development of spinal cord stimulation electrode: Advanced development for lower back pain treatment.
New product development for basivertebral nerve ablation: Initiated program for lower back pain treatment.
Drug delivery devices: Reported first preclinical sales to a large pharmaceutical company and initiated development for glioblastoma and other neurological disorders.
International commercial expansion: Initiated ISO 13485 certification process to support global sales.
Zimmer Biomet partnership: Expanded exclusive distribution agreement, contributing to significant revenue growth.
Revenue growth: Achieved 163% annual growth in product sales to $9.1 million and 907% quarterly growth to $2.7 million.
Improved gross margins: Increased product gross margins to 56.5% for the year.
Cost management: Reduced operating expenses by 5% for the year.
Capital raise: Strengthened balance sheet with $8.2 million capital raise.
Patent portfolio expansion: Granted new U.S. and European patents, bringing total to 17 issued and pending patents.
Pain management platform: Developing two technologies for lower back pain, including percutaneous paddle electrode and basivertebral nerve ablation system.
Drug delivery partnerships: Exploring partnerships for gene therapy, cell therapy, and glioblastoma drug delivery.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
NASDAQ compliance risk: The company has been granted a 180-day extension until May 4, 2026, to regain compliance with NASDAQ's minimum bid price rule for continued listing. Failure to meet this requirement could result in delisting from the NASDAQ Capital Market.
Regulatory approval dependency: The company's future growth in drug delivery and other platforms is dependent on gaining FDA clearance, which introduces regulatory risk.
Strategic partnership uncertainty: The company is in early discussions with potential partners for its pain management and drug delivery technologies. The lack of finalized agreements poses a risk to the commercialization and scaling of these platforms.
Market adoption challenges: While the company has reported initial success with its OneRF trigeminal nerve ablation system, broader market adoption and clinical validation are still in progress, which could impact revenue growth.
Supply chain and production risks: The company is expanding its product portfolio and entering new markets, which may strain its supply chain and production capabilities.
Economic and financial risks: Although the company has improved its financial position, it remains dependent on achieving key milestones to extend funding beyond fiscal 2026.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Financial Guidance for Fiscal Year 2026: The company plans to provide financial guidance for fiscal year 2026 once it receives a final forecast from its distribution partner, Zimmer Biomet.
Drug Delivery Program: The company aims to be commercially ready with its preclinical drug delivery offerings in 2026 and develop a pathway to gain FDA clearance. This program targets brain-related neurological disorders such as glioblastomas, epilepsy, and Parkinson's disease.
Pain Management Platform: Two active programs are in development for treating lower back pain: a percutaneously placed paddle electrode and a basivertebral nerve ablation system. Chronic animal studies for the paddle electrode are expected to finish in fiscal Q2 2026, with additional long-term studies to follow. The basivertebral nerve ablation system will undergo animal studies and continued R&D testing.
OneRF Trigeminal Nerve Ablation System: The company plans to continue limited commercial launches and perform additional cases to obtain post-market clinical performance information. Discussions are ongoing with a strategic partner to potentially license this technology.
OneRF Brain Ablation System: The company expects increased revenue from this system, which is marketed by Zimmer Biomet. Clinical outcomes have been positive, and the product is being released to additional sites. A registry is being established to gather performance data.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Should we expect any more face pain procedures before year-end?
A:Three other centers have indicated they have cases planned, but there are logistical issues such as obtaining ancillary equipment and generator installation. There is a good chance more cases will be done this month.
Q:Were the two recent face pain procedures done back-to-back, and is this feasible for future cases?
A:Yes, the two cases were done back-to-back, though not necessarily within an hour. This scheduling approach is feasible and convenient for future cases.
Q:At what point would the company proceed without a strategic partner?
A:If discussions with a strategic partner do not appear fruitful, the company could proceed independently. However, management is confident in reaching an agreement with a partner.
Q:Will there be more orders from the large pharma player for drug delivery devices?
A:Additional units for preclinical testing are expected to be shipped around midyear. Current efforts are focused on manufacturing devices and validating processes.
Q:What is the timing for establishing and opening the epilepsy registry?
A:The protocol is ready, but site-specific internal processes and administrative sign-offs are required. The registry is expected to open in Q2.
Q:What strategies are being implemented to raise patient awareness for epilepsy treatment?
A:The company is partnering with organizations like Cure and the Epilepsy Foundation. They are also sharing patient success stories, such as a professional pianist resuming his career after treatment.
Q:Can you expand on the distribution agreement with Zimmer Biomet?
A:The agreement was expanded a year ago to include brain ablation systems in addition to diagnostic sEEG electrodes. There is potential for further expansion to include facial pain technology.
Q:What is the development program for lower back pain treatment?
A:There are two programs: one for a paddle electrode placed percutaneously, and another for a Basivertebral Nerve Ablation system. Both involve leveraging existing technology and partnering with established companies for pulse generators and accessories.
Q:Does Zimmer Biomet have distribution rights for facial pain or lower back pain programs?
A:No, Zimmer Biomet does not have distribution rights for these programs. Discussions for lower back pain are with other strategic partners.
Q:How is the company navigating the reimbursement landscape for its technologies?
A:Reimbursement codes vary by device. Brain ablation procedures have been done at the patient's bedside, avoiding operating room costs. Neurosurgeons see the value of the technology, and reimbursement has not been a hindrance so far.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timing of additional face pain procedures, stating only that there is a 'good chance' more cases will be done this month. Similarly, they did not provide a clear timeline for reaching an agreement with a strategic partner, only expressing confidence in the process. For the epilepsy registry, while Q2 was mentioned as a target, the timeline remains uncertain due to site-specific administrative processes. Additionally, the response on reimbursement challenges was broad and lacked specific examples or data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
FDA clearance
McClurg Chief
NASDAQ
OneRF brain
OneRF nerve
RD
Society
animal study
bid price
capability case
caregiver
clearance OneRF
commercialization
compliance
contact
control probe
expansion
extension
glioblastoma
goal
interest
meeting
notice allowance
organization
pain platform
patent
physician
portfolio
probe placement
sEEG
sale
system probe
temperature control
testing
therapy
use
NMTC Transcript
NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call Transcript
Positive5-12
The earnings call highlights a strong 72% YoY revenue growth for the OneRF brain ablation system, signaling robust product demand. Despite the lack of strategic initiative details and shareholder return plans, the financial performance is a significant positive factor. The absence of clear management responses in the Q&A indicates some uncertainty, but the strong product revenue growth outweighs these concerns, leading to a positive sentiment.
NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Earnings Call Transcript
Unknown2-17
The earnings call reveals several concerns: a decrease in product and license revenue, increased net loss, and reduced cash reserves. While there are positive clinical outcomes and ongoing strategic partnerships, the company's avoidance of specific operational details and reliance on Zimmer for sales and marketing raise uncertainties. The Q&A section highlights operational risks, market penetration challenges, and competitive pressures. Despite some positive product developments, the overall sentiment is negative due to financial underperformance and unclear future guidance.
NeuroOne Medical Technologies Corporation (NMTC) Q4 2025 Earnings Call Transcript
Positive12-17
The earnings call reveals strong financial performance with significant improvements in gross margins and a reduced net loss. The strategic plan outlines ambitious growth prospects, including new product developments and market expansions. Although some uncertainty exists around partnerships and timelines, the overall sentiment is optimistic with increased revenue guidance and improved financial health. The Q&A section did not highlight any major concerns, supporting a positive outlook. Given these factors, a positive stock price movement is likely over the next two weeks.
NeuroOne Medical Technologies Corporation (NMTC) Q3 2025 Earnings Call Transcript
Positive8-14
The earnings call reveals strong financial performance, with significant revenue and margin growth, reduced expenses, and improved net loss. The partnership with Zimmer Biomet and international expansion plans are promising. Despite management's cautious stance on 2026 guidance, the optimistic FY 2025 outlook and strategic partnerships suggest a strong positive sentiment. The Q&A session highlights potential growth areas and addresses concerns, further solidifying the positive outlook. Given the context and potential for expansion, a strong positive stock price movement is expected, likely exceeding 8%.
NMTC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
